NCT04043338View on ClinicalTrials.gov

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

PHASE1UnknownINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

August 11, 2019

Primary Completion Date

January 30, 2022

Study Completion Date

April 30, 2022

Conditions

Parkinson's Disease

Interventions

DRUG

XC130-A10H

XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets

DRUG

Placebo

Placebo supplied as matching capsules or tablets

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Xoc Pharmaceuticals

Collaborators (1)

All Listed Sponsors

collaborator

Celerion

INDUSTRY

lead

Xoc Pharmaceuticals

INDUSTRY